Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Rheumatology and Therapy
|
November 10, 2021
A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
Stanley Cohen, Viatcheslav R Akmaev, Johanna B Withers, et al.
Lupus Science & Medicine
|
May 14, 2020
Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
Anca D Askanase, Enxu Zhao, Julie Zhu, et al.
Expert Opinion on Biological Therapy
|
April 20, 2022
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis
Vibeke Strand, Lixia Zhang, Alix Arnaud, et al.
Rheumatology and Therapy
|
March 19, 2020
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Roy Fleischmann, Daniel E Furst, Erin Connolly-Strong, et al.
Open Access Rheumatology : Research and Reviews
|
July 2, 2020
Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
Laura Bartels-Peculis, Ajay Sharma, Alison M Edwards, et al.
Journal of Managed Care & Specialty Pharmacy
|
February 28, 2020
Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden
Patricia Katz, Winnie W Nelson, R Paola Daly, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
July 20, 2020
Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus
Patricia Katz, George J Wan, Paola Daly, et al.
Journal of Managed Care & Specialty Pharmacy
|
October 20, 2021
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility
Christopher Arnell, Martin Bergman, Dhiman Basu, et al.
Expert Review of Molecular Diagnostics
|
December 23, 2021
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
Vibeke Strand, Stanley B Cohen, Jeffrey R Curtis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
CGE25-108: Uncovering APOBEC Mutational Signatures in Cancer: The Power of Whole Genome Sequencing for Comprehensive Genomic Profiling
Erin Connolly-Strong, Ryul Kim, Brain Beak-Lok Oh, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Rheumatology and Therapy
|
November 10, 2021
A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
Stanley Cohen, Viatcheslav R Akmaev, Johanna B Withers, et al.
Lupus Science & Medicine
|
May 14, 2020
Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
Anca D Askanase, Enxu Zhao, Julie Zhu, et al.
Expert Opinion on Biological Therapy
|
April 20, 2022
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis
Vibeke Strand, Lixia Zhang, Alix Arnaud, et al.
Rheumatology and Therapy
|
March 19, 2020
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Roy Fleischmann, Daniel E Furst, Erin Connolly-Strong, et al.
Open Access Rheumatology : Research and Reviews
|
July 2, 2020
Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
Laura Bartels-Peculis, Ajay Sharma, Alison M Edwards, et al.
Journal of Managed Care & Specialty Pharmacy
|
February 28, 2020
Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden
Patricia Katz, Winnie W Nelson, R Paola Daly, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
July 20, 2020
Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus
Patricia Katz, George J Wan, Paola Daly, et al.
Journal of Managed Care & Specialty Pharmacy
|
October 20, 2021
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility
Christopher Arnell, Martin Bergman, Dhiman Basu, et al.
Expert Review of Molecular Diagnostics
|
December 23, 2021
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
Vibeke Strand, Stanley B Cohen, Jeffrey R Curtis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
CGE25-108: Uncovering APOBEC Mutational Signatures in Cancer: The Power of Whole Genome Sequencing for Comprehensive Genomic Profiling
Erin Connolly-Strong, Ryul Kim, Brain Beak-Lok Oh, et al.
Page
of 2